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Background: Nitric oxide (NO) measurements in exhaled air and hypertonic saline-induced
sputum are commonly used biomarker sampling methods of the lower airways. Both sampling
methods have been validated in asthmatic patients and healthy controls, however, data from
chronic smokers are scarce.
Objectives: To evaluate the reproducibility and differences in fractional exhaled NO (FeNO)
values in asymptomatic chronic smokers and healthy, non-smoking controls. Furthermore, to
test the effect of hypertonic saline sputum induction (SI) on FeNO levels in both study
groups.
Methods: 16 asymptomatic chronic smokers and 16 non-smokers participated in this study.
Baseline FeNO and forced expiratory volume in 1 s (FEV1) were recorded pre- and 30 min
post NaCl 4.5% SI (3  5 min) on 2 study days (2 h; 4e10 days apart). Mixed ANOVA was
used to estimate the intra-subject Coefficient of Variation (CV) % over days; changes in FeNO
and FEV1 values before and after SI, were analyzed by a Student’s paired t-test.The differ-
ence between smokers and non-smokers was estimated by a Student’s t-test.
Results: On day 1, FeNO values in smokers were significantly lower than in non-smokers,
10.6 ppb, and 18.4 ppb, respectively, (42% difference, pZ 0.0028, 95% CI:59%,19%). In both
study groups, FeNO measurements were reproducible, with an intra-subject CV of 27.2% and
19.2%, for smokers and non-smokers, respectively. SI significantly decreased FeNO levels in both
study groups onday 1. In smokers, therewas amean reduction in FeNOof almost 37% (pZ 0.0045,asmus Medical Center, Depts of Allergology and Pulmonology, P.O.Box 2040, 3000 CA Rotterdam, The
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918 R.G.J.A. Zuiker et al.95% CI: 53%, 14%), and in non-smokers a mean decrease of almost 37% (95% CI : 53%, 14%;
pZ 0.0045). In both study groups SI did not affect FEV1 (p > 0.94).
Conclusions: Our data extend previous findings in asthmatics and healthy controls to asymptom-
atic chronic smokers: 1. FeNOmeasurements are reproducible in both smokers and non-smokers;
2. baseline FeNO levels in chronic smokers are lower than in non-smokers and 3. sputum induction
by hypertonic saline reduces FeNO levels in both study groups, without affecting lung function.
ª 2010 Elsevier Ltd. All rights reserved.Table 1 Subjects’ baseline characteristics.
Non-smokers Smokers
Number of subjects 16 16
Age (years) 41 (30e49) 41 (32e52)
Gender (M/F) 8M/8F 8M/8F
Height (meters) 1.75 (1.56e1.93) 1.73 (1.58e1.85)
Weight (kg) 77.5 (51.8e110.2) 73.1 (46.5e100.5)
BMI (kg/m2) 25.1 (21.1e29.5) 24.3 (18.6e30.0)
FEV1 (L) 3.66 (2.75e5.16) 3.55 (2.38e4.64)
FEV1 (% predicted) 102.9 (78e119.6) 102.7 (82.1e121.1)
FVC (L) 4.78 (3.21e6.42) 4.46 (3.15e6.38)
FVC (% predicted) 105.1 (82e131) 111.7 (76e127)
Values presented as mean (range).Introduction
Sputum induction by hypertonic saline (SI) and fractional
exhaled nitric oxide (FeNO) are validated, commonly used
non-invasive biomarker sampling methods of the lower
airways.1,2 FeNO measurements are increasingly applied for
diagnosis and monitoring of asthma.3 Furthermore, both
methods are often used as complementary research tools to
assess the airway inflammation in response to interventions
with (novel) anti-inflammatory therapeutic modalities.4
However, there is evidence that sampling methods some-
times interfere and thus may affect the levels of
biomarkers.5 So far, two published studies have addressed
the effect of SI on FeNO values in asymptomatic atopic
subjects and asthmatic patients and showed a maximal
decrease in FeNO directly post-induction with still
a substantial decrease up to 4 h after SI.6,7 In this study
population, FeNO levels were reproducible and unrelated
to the initial SI-induced decrease in FEV1.
6,7 So far, few
data have been published on chronic smokers.8,9 Therefore,
we tested the reproducibility and differences in FeNO
levels between asymptomatic chronic smokers and healthy
non-smokers. Furthermore, we investigated the effect of SI
on FeNO levels in both study groups.
Methods
Subjects
The study population consisted of two groups: 16 asymptom-
atic chronic smokerswitha smoking historyof at least 10pack-
years (8F/8M; 32e52 years) and 16 healthy non-smokers (8F/
8M; 30e49 years) who had not smoked for at least 12 months
prior to study enrolment and who had a total smoking history
of less than 5 pack-years. For the smoker group, the last
cigarettewas smoked at least 1 h before any study procedure.
All subjects had no history of relevant lung disease or any
respiratory tract infection for at least 4weeks before the start
of the study. All subjects gave written informed consent. The
study was approved by the Ethics Committee of Leiden
University Medical Centre, Leiden, Netherlands.
Study design
The study comprised two study days, 4e10 days apart. On
each study day, FeNO was measured approximately 55 min
before and 30 min after the SI-procedure. All assessments
were performed at the same time of the day (2 h). This
study was conducted as part of a larger biomarker study;
the focus of this manuscript is on methodological issues
related to the interaction of SI on FeNO levels.Fractional exhaled nitric oxide (FeNO)
FeNOmeasurementswereperformedbyachemiluminescence
analyser (Ecomedics CLD88sp, Ecomedics, Duernten,
Switzerland) according to current guidelines.1 Briefly, after
a deep inhalation of NO-free air, subjects exhaled for
approximately 10 s against a resistance at a stable flow of
approximately 50mL/s. Themeanof thefirst three technically
acceptable measurements (within 10%) were included in the
analysis and expressed in parts per billion (ppb).
Pulmonary function tests
Spirometry was performed according to standardized proto-
cols by a calibrated spirometer (Vmax Spectra Sensor Medics;
Cardinal Health, Houten, The Netherlands)10 connected to
a personal computer. Themean of the two out of three (within
5%) highest, technically satisfactory forced expiratory volume
in 1 s (FEV1) measurements was included in the analysis.
Hypertonic saline sputum induction
Sputum was induced by hypertonic saline (4.5% NaCl) neb-
ulised by an ultrasonic nebulizer (DeVilbiss Ultra NEB 2000,
Somerset, PA, USA) according to current guidelines during
three periods of 5 min each.2 Spirometry was performed
7 min after each SI-period.
Analysis
The reproducibility of the FeNO levels in both study groups
was assessed on log-transformed data by a Mixed Analysis of
Variance (ANOVA) to estimate the intra-subject Coefficient
of Variation (CV). The differences in FeNO levels between
both study populations were analyzed with a Student’s
t-test and the effect of inhaled NaCl 4.5% on FeNO and FEV1
Table 2 Effect of SI (NaCl 4.5%) on FeNO and FEV1 values.
Study population/parameters Day 1
Pre NaCl 4.5% 30 min post
NaCl 4.5%
Difference (95% CI) p-value
non-smokers
FeNO (ppb) 18.4 12.0 34.9%(57.3%,0.6%) p Z 0.047
FEV1 (L) 3.66 3.68 0.02 (0.38, 0.41) p Z 0.94
smokers
eNO (ppb) 10.6 6.7 36.6%(53.2%,14.2%) p Z 0.0045
FEV1 (L) 3.56 3.55 0.01(0.52,0.49) p Z 0.95
Study population/parameters Day 2
Pre NaCl 4.5% 30 min post
NaCL 4.5%
Difference (95% CI) p-value
non-smokers
FeNO (ppb) 15.9 12.3 22.6%(50.5%,21.1%) P Z 0.25
FEV1 (L) 3.56 3.68 0.12 (0.31, 0.57) P Z 0.56
smokers
FeNO (ppb) 11.1 8.5 23.9%(43.5%,2.6%) P Z 0.072
FEV1 (L) 3.49 3.53 0.04 (0.44, 0.52) P Z 0.86
Coefficient of variation (CV%) for
FeNO (pre NaCl 4.5%)
non-smokers 19.2%
smokers 27.2%
CI Z confidence interval. FeNO values in geometric means.
Nacl 4.5% reduces FeNo in smokers 919within both study groups was analyzed with the paired
Student’s t-test. Results were back-transformed to ratios
and expressed as percentage difference.
Results
Study subjects
The study groups were well-matched with no statistically
significant differences in baseline characteristics between
the two groups (Table 1).
Reproducibility and difference in FeNO between
study groups
The intra-subject mean CV for baseline FeNO measure-
ments was 19.2% and 27.2% for non-smokers and smokers,
respectively (Table 2). Mean FeNO was significantly lower in
smokers compared with non-smokers (Table 2).
Effect of sputum induction on FeNO and FEV1
On day 1, SI decreased FeNO levels in non-smokers by on
mean 35% (95% CI: 57%, 0.6%; pZ 0.047) and in smokers
by on mean 37% (95% CI:53%, 14%; pZ 0.0045) (Table 2).
SI did not affect FEV1 in either study group.
Discussion
In line with previous observations in allergic asthmatics, we
found reproducible FeNO levels in asymptomatic chronic
smokers and healthy non-smoking controls. In smokers, FeNO
levels were generally lower than in non-smokers and within
similar ranges as previously reported.11 Similarly to previousobservations in allergic asthmatics,6 hypertonic saline
decreased FeNO levels in both study groups without affecting
FEV1. Therefore, our findings confirm and extend previous
data.5e7,12
The sputum inductions in our study were performed
according to standardized procedures1 in age- and gender-
matched populations, while in the smokers the time
between smoking and any measurements was kept within
the same ranges.12 Hence, the lack of statistical signifi-
cance between both study groups and pre- and post-SI on
study day 2 is most probably due to a larger variability of
the FeNO values in a small sample size, possibly caused by
external factors.
In line with previous studies we found lower FeNO levels
in smokers compared with non-smokers.12 It appears that
smoking inhibits NO-formation from inducible nitric oxide
synthase in epithelial lung cells.13 Furthermore, NO-
synthesis may be reduced by negative feedback as a result
of high NO-concentrations in cigarette smoke,12 NO-oxida-
tion or interaction with other molecules present in tobacco
smoke.14
In conclusion, FeNO levels in chronic smokers were
found to be reproducible and generally lower than in
healthy non-smokers. Sputum induction reduced FeNO in
both study populations without affecting FEV1. Our data
extend previous observations in allergic asthmatics to
chronic smokers. In view of the interference of sputum
induction with FeNO measurements: FeNO should be
measured before sputum induction.
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